Literature DB >> 12167278

Attenuated infectivity of HIV type 1 from epithelial cells pretreated with a tight-binding nonnucleoside reverse transcriptase inhibitor.

Gadi Borkow1, Horacio Salomon, Mark A Wainberg, Michael A Parniak.   

Abstract

Short exposure of uninfected lymphocytes to UC781, a tight-binding nonnucleoside reverse transcriptase inhibitor (NNRTI), renders these cells refractory to subsequent HIV infection in the absence of exogenous drug (Borkow et al: J Virol 1997;71:3023-3030). Since epithelial cells may play a role in the sexual transmission of HIV-1, we examined the ability of NNRTI pretreatment to protect ME180 cervical epithelial cells and I407 intestinal epithelial cells from subsequent HIV-1 infection. Epithelial cells were pretreated with NNRTI, then exposed to HIV-1 chronically infected H9(+) cells for a short time following removal of the exogenous drug. The epithelial cells were productively infected by HIV-1, as shown by the presence of integrated HIV-1 proviral DNA, the presence of intracellular p24 antigen, and the production of nascent HIV-1 virions (cell-free p24) at various times postinfection. UC781 pretreatment of the epithelial cells did not prevent HIV-1 infection, since the cells had integrated proviral DNA, but the infectivity of virus subsequently produced from the UC781-treated cells was attenuated in a dose-dependent manner and virtually abolished at UC781 concentrations readily attainable in vivo. In contrast, nevirapine was ineffective in this respect, suggesting that not all NNRTI have microbicidal potential. The abrogation of infectivity of virus produced from UC781-pretreated epithelial cells suggests that this NNRTI may be useful in vaginal microbicide formulations targeted to inhibit HIV-1 in the vaginal/cervical or rectal milieus of a newly exposed individual.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12167278     DOI: 10.1089/088922202760072339

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  11 in total

1.  Lack of in vitro-in vivo correlation for a UC781-releasing vaginal ring in macaques.

Authors:  Christopher McConville; James M Smith; Clare F McCoy; Priya Srinivasan; James Mitchell; Angela Holder; Ron A Otten; Salvatore Butera; Gustavo F Doncel; David R Friend; R Karl Malcolm
Journal:  Drug Deliv Transl Res       Date:  2015-02       Impact factor: 4.617

2.  Advances in the Development of Microbicides for the Prevention of HIV Infection.

Authors:  Lucio R Minces; Ian McGowan
Journal:  Curr Infect Dis Rep       Date:  2010-01       Impact factor: 3.725

3.  Characterization of UC781-tenofovir combination gel products for HIV-1 infection prevention in an ex vivo ectocervical model.

Authors:  Marilyn Cost; Charlene S Dezzutti; Meredith R Clark; David R Friend; Ayman Akil; Lisa Cencia Rohan
Journal:  Antimicrob Agents Chemother       Date:  2012-03-19       Impact factor: 5.191

Review 4.  Vaginal microbicides: a novel approach to preventing sexual transmission of HIV.

Authors:  Gustavo Doncel; Christine Mauck
Journal:  Curr HIV/AIDS Rep       Date:  2004-04       Impact factor: 5.071

5.  Development and Characterization of a Vaginal Film Containing Dapivirine, a Non- nucleoside Reverse Transcriptase Inhibitor (NNRTI), for prevention of HIV-1 sexual transmission.

Authors:  Ayman Akil; Michael A Parniak; Charlene S Dezzuitti; Bernard J Moncla; Marilyn R Cost; Mingguang Li; Lisa Cencia Rohan
Journal:  Drug Deliv Transl Res       Date:  2011-06-01       Impact factor: 4.617

6.  In vitro microbicidal activity of the nonnucleoside reverse transcriptase inhibitor (NNRTI) UC781 against NNRTI-resistant human immunodeficiency virus type 1.

Authors:  Mohammad M Hossain; Michael A Parniak
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

7.  The nonnucleoside reverse transcriptase inhibitor UC-781 inhibits human immunodeficiency virus type 1 infection of human cervical tissue and dissemination by migratory cells.

Authors:  Patricia Fletcher; Yana Kiselyeva; Greg Wallace; Joseph Romano; George Griffin; Leonid Margolis; Robin Shattock
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

8.  In vitro comparison of topical microbicides for prevention of human immunodeficiency virus type 1 transmission.

Authors:  Charlene S Dezzutti; V Nicole James; Artur Ramos; Sharon T Sullivan; Aladin Siddig; Timothy J Bush; Lisa A Grohskopf; Lynn Paxton; Shambavi Subbarao; Clyde E Hart
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

9.  In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides.

Authors:  Yven Van Herrewege; Jo Michiels; Jens Van Roey; Katrien Fransen; Luc Kestens; Jan Balzarini; Paul Lewi; Guido Vanham; Paul Janssen
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

10.  Anti-HIV-1 activity of anti-TAR polyamide nucleic acid conjugated with various membrane transducing peptides.

Authors:  Snehlata Tripathi; Binay Chaubey; Sabyasachi Ganguly; Dylan Harris; Ralph A Casale; Virendra N Pandey
Journal:  Nucleic Acids Res       Date:  2005-08-02       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.